Delek US Holdings, Inc.
DKDelek US Holdings, Inc. is printing record margins on a fuller multiple. From here the earnings must do all the lifting.
Biggest watch item: margins are the best this company has ever printed — every ratio flatters at record profitability, so the whole story leans on margins holding.
The price is in a confirmed uptrend (44 weeks in) while the P/E sits at the 74th percentile of its own 2-year range. Underneath, the last four quarters read mixed, and 582% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Delek US Holdings, Inc. trades at $66.2, in a confirmed uptrend and 44 weeks into that stage. That is +59.1% against its own 200-day average. It sits at 96% of a 52-week range of $22 to $68. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 6 straight weeks.
Today the stock is in a confirmed uptrend — week 44 of stage 2. At $66.2 it trades +59.1% versus its 200-day average and sits at 96% of its 52-week range ($22–$68).
Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +420% while the S&P 500 moved +263% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 6 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Delek US Holdings, Inc. trades at 99.2× P/E, at the pricey end of its own range (74th percentile). Its long-run median P/E is 6.8×, measured across 2.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 99.2× is at the pricey end of its own range (74th percentile), against a long-run median of 6.8× measured over 2.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Delek US Holdings, Inc. reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 12 quarters across 2 curves, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −9.5% | −18.5% | — | — |
| Profit | — | −43.0% | — | — |
| Stock price | +218.7% | +34.0% | +31.5% | +16.6% |
4-Factor Sector Score
39.2/100 — rank 14 of 16 in Oil & Gas Refining & Marketing · 64% evidence confidence
Delek US Holdings, Inc. scores 39.2 out of 100 against the 16 companies it is compared with in Oil & Gas Refining & Marketing, ranking 14. Price leads the evidence: RS versus the benchmark is 50.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
The four contributions add to the total exactly: 8.2 + 3.7 + 9 + 18.3 = 39.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Delek US Holdings, Inc. reported $2.6 B of revenue in the Mar 26 quarter, +0.4% year on year. That is the 2nd straight quarter of year-on-year growth. Over 4 years it has compounded at 0.2% a year. The last full year, FY25, came in at $10.7 B. The last four reported quarters add to $10.7 B.
FY25 revenue came in at $10.7 B (−9.5% on the year), capping 4 years at 0.2% compound. The latest quarter (Mar 26) printed $2.6 B, +0.4% year on year — the 2nd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged −4.7% growth against the decade's 0.2% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −5.5% over the last 4 quarters against −17.9%/yr over the last 8 — accelerating.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Delek US Holdings, Inc.'s operating margin is −6.8% in the Mar 26 quarter, −1.9 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 5 fiscal years the operating margin has ranged −4.1% to 2.8%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is −6.8%, −1.9 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −4.1%–2.8%, and FY25's 2.8% is the top of that band — a record year.
🚨 Why the margin moved: operating margin went −1.9 pp year on year while gross margin went −2.2 pp — the loss came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Delek US Holdings, Inc. posted a net loss of $0.2 B in the Mar 26 quarter. Full-year FY25 profit was $0.1 B. That loss is 7.2% of the quarter's revenue. The same quarter a year earlier lost $0.2 B. 8 of the last 12 reported quarters were loss-making.
Mar 26 profit was $−0.2 B, null year on year. On the full year, FY25 printed $0.1 B (null).
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 582% of Delek US Holdings, Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $0.5 B of operating cash against $0.1 B of profit. After $0.5 B of capital spending, $0.0 B was left as free cash.
FY25: operating cash of $0.5 B against reported profit of $0.1 B, leaving free cash of $0.0 B after $0.5 B of capital spending. Across the last 3 fiscal years the conversion rate is 582% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Delek US Holdings, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $1.0 B over the last 3 years. Averaged over those years that is 3.1% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $1.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Delek US Holdings, Inc. earns a ROE of 9% in FY25. That is up from a trough of −103% in FY24. Return on invested capital clears the cost of that capital by +2.7 percentage points, so growth here adds value rather than only size. The wiring behind it is 0.5% net margin on 1.56× asset turns.
FY25 ROE is 9%, recovered from a FY24 trough of −103% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 0.5% net margin × 1.56× asset turns × 12.45× balance-sheet leverage ≈ 9.7% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 9.8% − 7.1% = a +2.7 pp spread. The 7.1% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
Delek US Holdings, Inc. paid $1.02 per share over the last four reported quarters, up 2.0% on a year ago. The most recent declaration was $0.26 for Mar 26. Against the current price of $66.2 that is a trailing yield of 1.54%, measured on dividends already paid rather than on a forecast.
Delek US Holdings, Inc. paid $1.02 per share across the last four reported quarters, most recently $0.26 for Mar 26. That is up 2.0% against the same quarter a year earlier. Against the current price of $66.2 the trailing twelve months work out to 1.54% — trailing dividends measured against today's price, not a forward estimate.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Delek US Holdings, Inc. carries total debt of $3.3 B against shareholder equity of $0.3 B as of Mar 26, a debt-to-equity of 10.83. On the annual view that ratio went from 2.40 in FY21 to 6.02 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of $3.3 B against shareholder equity of $0.3 B — a debt-to-equity of 10.83. On the annual view, debt-to-equity went from 2.40 (FY21) to 6.02 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
10.7% of Delek US Holdings, Inc.'s tradable float is currently sold short — a large bloc is positioned against it. At typical trading volumes those positions would take about 5.0 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 10.7% of the float is sold short, and at typical trading volumes it would take about 5.0 days to buy those positions back. A large bloc is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Delek US Holdings, Inc.: the Z-score reads 1.47. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits inside the distress zone. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
🚨 Why it matters: a Z-score of 1.47 is inside the distress zone — the balance sheet is a real risk, not a detail.
The safety line in one sentence: the Z-score reads 1.47.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1PBF Energy Inc.PBF | 68.3/100Thin evidence · provisional58% evidence | BREAKING OUT | 23.0/35 Revenue — · PAT — · OPM change 11 pp 45% evidence | 13.8/25 ROCE 12.9% · OPM 3.8% 76% evidence | 11.5/20 P/E 4× · PEG — 15% evidence | 20.0/20 RS sector 36.8% · RS bench 55.3% · 1Y 199.2%6 of 12 weeks ahead 100% evidence |
| Exact sum: 23 + 13.8 + 11.5 + 20 = 68.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 2Valero Energy CorporationVLO | 65.2/100Thin evidence · provisional58% evidence | BREAKING OUT | 23.1/35 Revenue — · PAT — · OPM change 8.3 pp 45% evidence | 15.2/25 ROCE 11.5% · OPM 5.3% 76% evidence | 10.6/20 P/E 10.8× · PEG — 15% evidence | 16.3/20 RS sector 16.7% · RS bench 33.2% · 1Y 131.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 23.1 + 15.2 + 10.6 + 16.3 = 65.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 3Star Group, L.P.SGU | 61.6/100Mixed-positive evidence75% evidence | BASING | 21.6/35 Revenue 3.2% · PAT 34.3% · OPM change 3.6 pp 83% evidence | 18.8/25 ROCE 22.6% · OPM 20.5% 76% evidence | 16.3/20 P/E 4.2× · PEG 0.09 65% evidence | 4.9/20 RS sector -19.5% · RS bench -6.7% · 1Y 9.3%0 of 12 weeks ahead 70% evidence |
| Exact sum: 21.6 + 18.8 + 16.3 + 4.9 = 61.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Marathon Petroleum CorporationMPC | 60.1/100Mixed-positive evidence81% evidence | BREAKING OUT | 20.5/35 Revenue -1.7% · PAT 55.6% · OPM change 1.9 pp 83% evidence | 10.9/25 ROCE 2.3% · OPM 4.1% 76% evidence | 12.7/20 P/E 15.9× · PEG 0.36 65% evidence | 16.0/20 RS sector 13.9% · RS bench 30.3% · 1Y 94.4%8 of 12 weeks ahead 100% evidence |
| Exact sum: 20.5 + 10.9 + 12.7 + 16 = 60.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5HF Sinclair CorporationDINO | 59.9/100Thin evidence · provisional58% evidence | BREAKING OUT | 21.6/35 Revenue — · PAT — · OPM change 10.6 pp 45% evidence | 13.0/25 ROCE 8% · OPM 11.9% 76% evidence | 11.0/20 P/E 6.6× · PEG — 15% evidence | 14.3/20 RS sector 17.1% · RS bench 34.1% · 1Y 102.6%10 of 12 weeks ahead 100% evidence |
| Exact sum: 21.6 + 13 + 11 + 14.3 = 59.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6Sunoco LPSUN | 55.7/100Mixed-positive evidence81% evidence | TURNING | 21.1/35 Revenue 37.3% · PAT 13.3% · OPM change 2.4 pp 83% evidence | 13.6/25 ROCE 4.5% · OPM 8.1% 76% evidence | 12.1/20 P/E 14.3× · PEG 0.63 65% evidence | 8.9/20 RS sector -3.2% · RS bench 11.3% · 1Y 42.6%4 of 12 weeks ahead 100% evidence |
| Exact sum: 21.1 + 13.6 + 12.1 + 8.9 = 55.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Par Pacific Holdings, Inc.PARR | 55.0/100Mixed-positive evidence64% evidence | TURNING | 18.7/35 Revenue -2.5% · PAT — · OPM change 4.5 pp 62% evidence | 9.1/25 ROCE 2.3% · OPM 3.6% 76% evidence | 10.8/20 P/E 7× · PEG — 15% evidence | 16.4/20 RS sector 35.2% · RS bench 53.3% · 1Y 204%6 of 12 weeks ahead 100% evidence |
| Exact sum: 18.7 + 9.1 + 10.8 + 16.4 = 55 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8World Kinect CorporationWKC | 52.0/100Thin evidence · provisional52% evidence | BREAKING OUT | 20.2/35 Revenue — · PAT — · OPM change 0.7 pp 45% evidence | 10.0/25 ROCE 3.5% · OPM 0.6% 76% evidence | 8.7/20 P/E 118.2× · PEG — 15% evidence | 13.1/20 RS sector 11.8% · RS bench 29.1% · 1Y 53.8%12 of 12 weeks ahead 70% evidence |
| Exact sum: 20.2 + 10 + 8.7 + 13.1 = 52 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Phillips 66PSX | 49.0/100Thin evidence · provisional58% evidence | BREAKING OUT | 17.5/35 Revenue — · PAT — · OPM change 1.7 pp 45% evidence | 8.7/25 ROCE 0.2% · OPM 0.3% 76% evidence | 9.4/20 P/E 17.9× · PEG — 15% evidence | 13.4/20 RS sector 3.6% · RS bench 18.8% · 1Y 72.8%6 of 12 weeks ahead 100% evidence |
| Exact sum: 17.5 + 8.7 + 9.4 + 13.4 = 49 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10CrossAmerica Partners LPCAPL | 43.0/100Mixed-negative evidence74% evidence | BASING | 16.8/35 Revenue -9.4% · PAT 81.8% · OPM change 2.6 pp 62% evidence | 10.0/25 ROCE 2.7% · OPM 2.8% 76% evidence | 14.3/20 P/E 13.9× · PEG 0.32 65% evidence | 1.9/20 RS sector -22.3% · RS bench -9.9% · 1Y 5.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.8 + 10 + 14.3 + 1.9 = 43 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Delek Logistics Partners, LPDKL | 40.8/100Mixed-negative evidence81% evidence | TURNING | 14.8/35 Revenue 12.9% · PAT 14.1% · OPM change -5.6 pp 83% evidence | 11.6/25 ROCE 1.7% · OPM 13.4% 76% evidence | 5.4/20 P/E 15.7× · PEG 2.77 65% evidence | 9.0/20 RS sector -7.9% · RS bench 6.2% · 1Y 33.6%4 of 12 weeks ahead 100% evidence |
| Exact sum: 14.8 + 11.6 + 5.4 + 9 = 40.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12CVR Energy, Inc.CVI | 39.9/100Thin evidence · provisional58% evidence | ASLEEP | 18.9/35 Revenue — · PAT — · OPM change 0.7 pp 45% evidence | 8.8/25 ROCE 2.8% · OPM -7.3% 76% evidence | 9.2/20 P/E 40.5× · PEG — 15% evidence | 3.0/20 RS sector -15.9% · RS bench -2.8% · 1Y 28.1%4 of 12 weeks ahead 100% evidence |
| Exact sum: 18.9 + 8.8 + 9.2 + 3 = 39.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Clean Energy Fuels Corp.CLNE | 39.8/100Thin evidence · provisional55% evidence | ASLEEP | 22.3/35 Revenue 5.5% · PAT — · OPM change 119.2 pp 62% evidence | 4.5/25 ROCE -0.3% · OPM -2.5% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.0/20 RS sector -37.9% · RS bench -27.8% · 1Y -18.3%0 of 12 weeks ahead 70% evidence |
| Exact sum: 22.3 + 4.5 + 10 + 3 = 39.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Delek US Holdings, Inc.this pageDK | 39.2/100Mixed-negative evidence64% evidence | BREAKING OUT | 8.2/35 Revenue -5.6% · PAT — · OPM change -2 pp 62% evidence | 3.7/25 ROCE -4.3% · OPM -6.8% 76% evidence | 9.0/20 P/E 86× · PEG — 15% evidence | 18.3/20 RS sector 32.4% · RS bench 50.7% · 1Y 220.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 8.2 + 3.7 + 9 + 18.3 = 39.2 · Decision use: Price leads the evidence: RS versus the benchmark is 50.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 15Icahn Enterprises L.P.IEP | 30.5/100Adverse evidence64% evidence | BASING | 16.4/35 Revenue 6.2% · PAT — · OPM change 5.8 pp 62% evidence | 3.7/25 ROCE -4.2% · OPM -21.9% 76% evidence | 8.5/20 P/E 277.5× · PEG — 15% evidence | 1.9/20 RS sector -24.9% · RS bench -12.6% · 1Y -16.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.4 + 3.7 + 8.5 + 1.9 = 30.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16ARKO Petroleum Corp.APC | 48.2/100Thin evidence · provisional33% evidence | TURNING | 15.7/35 Revenue — · PAT — · OPM change 0.3 pp 39% evidence | 12.5/25 ROCE 3.6% · OPM 1.5% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —2 of 12 weeks ahead 0% evidence |
| Exact sum: 15.7 + 12.5 + 10 + 10 = 48.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Delek US Holdings, Inc.'s stock price today?
Delek US Holdings, Inc. trades at $66.2, +218.7% over the past year. The company is valued at $4.0 B. The stock sits at 96% of its 52-week range of $22–$68, +59.1% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 44 weeks in. — as of 5 August 2026.
What were Delek US Holdings, Inc.'s latest quarterly results?
Delek US Holdings, Inc. reported revenue of $2.6 B and a net loss of $0.2 B for the Mar 26 quarter. Earnings per share were $−3.34. The operating margin was −6.8%, 1.9 pp lower than a year earlier. — as of 5 August 2026.
What is Delek US Holdings, Inc.'s revenue?
Delek US Holdings, Inc. reported revenue of $2.6 B in the Mar 26 quarter, +0.4% year on year. For the full FY25 fiscal year, revenue was $10.7 B (−9.5%). Over the last 4 years revenue compounded at 0.2% a year. — as of 5 August 2026.
What is Delek US Holdings, Inc.'s profit?
Delek US Holdings, Inc. earned $−0.2 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $0.1 B. The operating margin ran −6.8% in the latest quarter. — as of 5 August 2026.
What is Delek US Holdings, Inc.'s market cap?
Delek US Holdings, Inc.'s market capitalisation is $4.0 B at a stock price of $66.2. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
What is Delek US Holdings, Inc.'s P/E ratio?
Delek US Holdings, Inc. trades at a P/E of 99.2×, at the 74th percentile of its own 2-year range, against a long-run median of 6.8×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.
Does Delek US Holdings, Inc. pay a dividend?
Yes — Delek US Holdings, Inc. declared $0.26 per share for Mar 26, and $1.02 per share across the last four reported quarters. The latest quarter is up 2.0% on the same quarter a year earlier. — as of 5 August 2026.
What is Delek US Holdings, Inc.'s dividend per share?
Delek US Holdings, Inc.'s most recently declared dividend is $0.26 per share for Mar 26, giving $1.02 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 5 August 2026.
What is Delek US Holdings, Inc.'s dividend yield?
Delek US Holdings, Inc.'s trailing dividend yield is 1.54%: $1.02 declared per share across the last four reported quarters, against a share price of $66.2. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 5 August 2026.
Is Delek US Holdings, Inc. overvalued?
On its own history, Delek US Holdings, Inc. looks expensive against its own history: its P/E of 99.2× sits at the 74th percentile of its 2-year range (long-run median 6.8×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 5 August 2026.
How is Delek US Holdings, Inc. performing?
Delek US Holdings, Inc. is in a confirmed uptrend, 44 weeks in. Against the S&P 500 it has been ahead on a trailing-13-week view for 6 weeks. This describes what the data did, not a rating. — as of 5 August 2026.
Is Delek US Holdings, Inc. in an uptrend?
Yes — the price is in a confirmed uptrend (week 44 of stage 2), trading +59.1% versus its 200-day average and at 96% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is Delek US Holdings, Inc. beating the market?
On recent form, yes — Delek US Holdings, Inc. has been ahead of the S&P 500 on a trailing-13-week view for 6 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +420% against the S&P 500's +263% — ahead of the index over the full window. — as of 5 August 2026.
Will Delek US Holdings, Inc.'s stock price go up?
This page publishes no price forecast for Delek US Holdings, Inc. What it measures instead: the stock price is $66.2, the price is in a confirmed uptrend 44 weeks in. Its P/E of 99.2× sits at the 74th percentile of its own 2-year range. — as of 5 August 2026.
Is the market betting against Delek US Holdings, Inc.?
Yes — short interest is 10.7% of Delek US Holdings, Inc.'s tradable float, about 5.0 days to cover at typical volumes. A crowded short: a large bloc is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
Does Delek US Holdings, Inc. have too much debt?
It carries real leverage — Delek US Holdings, Inc.'s debt-to-equity is 11.25. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 5 August 2026.
What is Delek US Holdings, Inc.'s capex?
Delek US Holdings, Inc. spent $1.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.5 B. — as of 5 August 2026.
What is Delek US Holdings, Inc.'s cash flow?
Delek US Holdings, Inc. generated $0.5 B of operating cash flow in FY25 and $0.0 B of free cash flow after $0.5 B of capital spending. Reported profit that year was $0.1 B, so operating cash ran ahead of profit. — as of 5 August 2026.
Is Delek US Holdings, Inc.'s profit real cash?
Yes — over the last 3 fiscal years, 582% of Delek US Holdings, Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $0.5 B against reported profit of $0.1 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.
How financially safe is Delek US Holdings, Inc.?
On the balance sheet, the Z-score reads 1.47 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is inside the danger band — a real balance-sheet risk. — as of 5 August 2026.
Where is Delek US Holdings, Inc. in its business cycle?
Delek US Holdings, Inc.'s FY25 operating margin was 2.8%, against a 5-year band of −4.1%–2.8%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran −6.8%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the Delek US Holdings, Inc. story?
Biggest watch item: margins are the best this company has ever printed — every ratio flatters at record profitability, so the whole story leans on margins holding. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is Delek US Holdings, Inc. a stock worth studying right now?
This is not investment advice. The machine read: Delek US Holdings, Inc. is printing record margins on a fuller multiple. From here the earnings must do all the lifting. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.